|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Danish Headache Center EUROHEAD-partners |
|---|---|
| Information provided by: | Danish Headache Center |
| ClinicalTrials.gov Identifier: | NCT00257985 |
Purpose
The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to GTN infusion.
| Condition | Intervention |
|---|---|
|
Familial Hemiplegic Migraine Type 1 and 2 Healthy Volunteers |
Drug: GTN |
| Study Type: | Interventional |
| Study Design: | Educational/Counseling/Training, Non-Randomized, Single Blind, Active Control, Single Group Assignment, Pharmacodynamics Study |
| Official Title: | Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2 |
| Estimated Enrollment: | 30 |
| Study Start Date: | April 2005 |
| Estimated Study Completion Date: | March 2006 |
Glyceryl trinitrate (GTN) induces migraine attacks indistinguishable from spontaneous attacks in approximately 80% of migraine sufferers. After systemic administration GTN is transformed to nitric oxide (NO). Treatment of spontaneous migraine attacks with an inhibitor of NO is effective in 60% of patients. These data show that NO is involved in both initiation and maintenance of migraine attack.
The consequence of migraine gene mutations on relevant migraine pathways has never been tested. The aim of the present study is to explore functional consequences of migraine gene mutations on their responses to GTN infusion. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients: Diagnosis of familial hemiplegic migraine (IHS-classification criteria) caused by mutations in the CACNA1A gene and the ATP1A2 gene. Controls: healthy volunteers
Exclusion Criteria:
Controls: No primary headache in their own history
Patients and controls:
On the study day:
Contacts and Locations| Denmark | |
| Danish Headache Center, University of Copenhagen, Department of Neurology, Glostrup Hospital | |
| Glostrup, Copenhagen, Denmark, DK-2600 | |
| Principal Investigator: | Jakob Møller Hansen, MD | Danish Headache Center |
More Information
| Study ID Numbers: | FHM-GTN 2005 |
| Study First Received: | November 22, 2005 |
| Last Updated: | July 31, 2006 |
| ClinicalTrials.gov Identifier: | NCT00257985 History of Changes |
| Health Authority: | Denmark: Den Centrale Videnskabsetiske Komité |
|
Familial hemiplegic migraine type 1 and 2 GTN middle cerebral artery |
superficial temporal artery headache genotype |
|
Vasodilator Agents Central Nervous System Diseases Pain Headache Disorders, Primary Cardiovascular Agents Healthy Brain Diseases |
Headache Disorders Nitroglycerin Signs and Symptoms Migraine Disorders Headache Neurologic Manifestations Migraine with Aura |
|
Vasodilator Agents Nervous System Diseases Central Nervous System Diseases Pain Headache Disorders, Primary Cardiovascular Agents Brain Diseases Pharmacologic Actions |
Headache Disorders Nitroglycerin Signs and Symptoms Migraine Disorders Therapeutic Uses Headache Neurologic Manifestations Migraine with Aura |
